Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Bafiertam (monomethyl fumarate)
- rilonacept
Interactions between your drugs
rilonacept monomethyl fumarate
Applies to: rilonacept, Bafiertam (monomethyl fumarate)
GENERALLY AVOID: The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution. Interleukin-1 blockers should be discontinued if neutropenia or serious infection occurs.
References (3)
- (2001) "Product Information. Kineret (anakinra)." Amgen
- (2008) "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc
- (2009) "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Kesimpta
Kesimpta (ofatumumab) is used to treat relapsing forms of multiple sclerosis. Includes Kesimpta ...
Copaxone
Copaxone is used to treat relapsing forms of multiple sclerosis (MS) in adults (including ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Tecfidera
Tecfidera (dimethyl fumarate) is used to treat relapsing forms of multiple sclerosis. Learn about ...
Aubagio
Aubagio (teriflunomide) is used to reduce flare-ups in people with relapsing multiple sclerosis ...
Avonex
Avonex is an interferon used to treat relapsing multiple sclerosis. It is given by injection into a ...
Gilenya
Gilenya (fingolimod) is used to treat relapsing forms of multiple sclerosis. Includes Gilenya side ...
Tysabri
Tysabri is used to treat multiple sclerosis and Crohn's disease. Learn about side effects ...
Ampyra
Ampyra (dalfampridine) is used to improve walking in patients with multiple sclerosis. Includes ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.